Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

NetraMark Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

NetraMark Holdings şirketinin toplam hissedar öz sermayesi CA$285.2K ve toplam borcu CA$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CA$523.0K ve CA$237.8K dir.

Anahtar bilgiler

Borç/özkaynak oranı

CA$0

Borç

Faiz karşılama oranı	n/a
Nakit	CA$350.98k
Eşitlik	CA$285.15k
Toplam yükümlülükler	CA$237.83k
Toplam varlıklar	CA$522.98k

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: PF0 'nin kısa vadeli varlıkları ( CA$523.0K ) kısa vadeli yükümlülüklerini ( CA$237.8K ) aşıyor.

Uzun Vadeli Yükümlülükler: PF0 un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: PF0 borçsuzdur.

Borcun Azaltılması: PF0 un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: PF0 şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: PF0 un, serbest nakit akışı her yıl % 14.3 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

NetraMark Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Less than half of directors are independent

NetraMark Holdings Inc. Announces Board Changes

NetraMark Holdings Inc. Expands Product Offerings to Enhance Clinical Trial Outcomes and Improve Market Access Strategy

New major risk - Market cap size

Third quarter 2024 earnings released: CA$0.013 loss per share (vs CA$0.037 loss in 3Q 2023)

Second quarter 2024 earnings released: CA$0.011 loss per share (vs CA$0.03 loss in 2Q 2023)

Netramark's Ai-Based Clinical Solution Identifies Novel Lung and Colon Cancer Biomarkers and Patient Subpopulations

NetraMark Holdings Inc. announces appointment of Jeff Huntsman to its strategic advisory board

First quarter 2024 earnings released: CA$0.013 loss per share (vs CA$0.045 loss in 1Q 2023)

NetraMark Holdings Inc. Announces Launch of the NetraAI Lab Offering

New major risk - Financial position

NetraMark's Generative AI Discovers Novel Rare Disease Drug Targets and Unique Patient Subpopulations That Could Substantially Improve Clinical Trial Success Rates

NetraMark Holdings Inc. Announces Management Changes

New major risk - Shareholder dilution

NetraMark Holdings Inc. announced that it has received CAD 2 million in funding

NetraMark Holdings Inc. announced that it expects to receive CAD 1.5 million in funding

New major risk - Financial position

New major risk - Market cap size

NetraMark Holdings Inc. Appoints Dr. Maryanne Rizk to Its Strategic Advisory Board

NetraMark Holdings Inc. announced that it has received CAD 0.74235 million in funding

NetraMark Holdings Inc. announced that it expects to receive CAD 0.5 million in funding

Netramark, to Launch Clinical Trial De-Risking Technology That Integrates Chatgpt

Nurosene Health Inc., Annual General Meeting, Mar 23, 2023

Less than half of directors are independent

Nurosene Health Inc. announced that it has received CAD 0.80225 million in funding

Nurosene Health Inc. announced that it has received CAD 0.07475 million in funding

Nurosene Health Inc. announced that it has received CAD 0.7275 million in funding

Nurosene Health Inc. Appoints Neurosurgeon Douglas James Cook as Chief Medical Officer

Nurosene Health Inc. Appoints Dhananja Jayalath to Its Advisory Board

Nurosene Health Inc. Appoints Dr. Luca Pani as Chief Innovation and Regulatory Officer

Nurosene Health Inc. Appoints Swapan Kakumanu as Chief Financial Officer

Nurosene Health Inc. Announces Resignation of Blake Sing as Chief Financial Officer

Nurosene Health Inc. announced that it has received CAD 0.595 million in funding

Less than half of directors are independent

Nurosene Health Inc. Appoints Gino DeMichele to its Board of Directors

Nurosene Health Inc. Advances Brain Health with the Launch of its Science-First Nuro App

Nurosene Announces Executive Changes

Nurosene Health Inc. Introduces NetraPlacebo

Nurosene Health Inc. Announces Resignation of Kirstine Stewart as Director

Nurosene Health Inc., Annual General Meeting, Apr 01, 2022

Chairman of the Board recently bought €84k worth of stock

Nurosene Health Inc. Releases Preliminary Findings That Support the Innovation of Anti-Aging Therapeutics

High number of new and inexperienced directors

Nurosene Health Inc. (CNSX:MEND) entered into a non-binding term sheet to acquire NetraMark Incorporated for CAD 15 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin